Anxiety/Depression Linked to HRQoL Losses in Seropositive RA
MONDAY, Nov. 4, 2024 -- Patients with seropositive rheumatoid arthritis (RA) with moderate and extreme anxiety/depression have mean health-related quality-of-life (HRQoL) losses, regardless of pain and discomfort, according to a study published online Oct. 30 in Clinical Rheumatology.
Diego Fernando Rojas‑Gualdrón, from the Universidad CES in Medellín, Colombia, and colleagues conducted a data analysis on a registry-based retrospective follow-up study of patients with seropositive RA treated between August 2014 and January 2023. The authors sought to examine the HRQoL loss associated with self-perceived anxiety/depression. A total of 3,579 patients were included, with a mean follow-up of 2.9 years.
The researchers found that 6.6 percent of the participants reported extreme anxiety/depression at program admission. Per year lived with seropositive RA, the average HRQoL loss was 3.4 months. Moderate and extreme anxiety/depression were associated with mean HRQoL losses of 2.2 and 4.1 months, respectively, among patients with no pain and discomfort, and with losses of 0.8 and 1.9 months, respectively, for patients with extreme pain/discomfort.
"These findings highlight the importance of strengthening mental health care and psychological well-being interventions for patients with RA, regardless of pain or disease activity," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis
THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...
Dementia Odds Significantly Increase With More Psychiatric Comorbidities
WEDNESDAY, Sept. 10, 2025 -- Dementia odds significantly increase with the number of psychiatric comorbidities, according to a study published online Sept. 9 in BMJ Mental...
Single Psychedelic Dose Reduces Symptoms of Generalized Anxiety Disorder
WEDNESDAY, Sept. 10, 2025 -- A single dose of a pharmaceutical formulation of LSD provides significant relief for patients with moderate-to-severe generalized anxiety disorder...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.